225 related articles for article (PubMed ID: 21569821)
21. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
22. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
23. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
24. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
25. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
[TBL] [Abstract][Full Text] [Related]
26. Soluble glucocorticoid-induced tumor necrosis factor receptor stimulates osteoclastogenesis by down-regulation of osteoprotegerin in bone marrow stromal cells.
Shin HH; Kim SJ; Kang SY; Lee DS; Choi HS
Bone; 2006 Oct; 39(4):716-23. PubMed ID: 16750437
[TBL] [Abstract][Full Text] [Related]
27. Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity.
Trentin L; Miorin M; Facco M; Baesso I; Carraro S; Cabrelle A; Maschio N; Bortoli M; Binotto G; Piazza F; Adami F; Zambello R; Agostini C; Semenzato G
Br J Haematol; 2007 Sep; 138(5):594-602. PubMed ID: 17686053
[TBL] [Abstract][Full Text] [Related]
28. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
29. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
[TBL] [Abstract][Full Text] [Related]
30. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation.
Lai FP; Cole-Sinclair M; Cheng WJ; Quinn JM; Gillespie MT; Sentry JW; Schneider HG
Br J Haematol; 2004 Jul; 126(2):192-201. PubMed ID: 15238139
[TBL] [Abstract][Full Text] [Related]
31. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
[TBL] [Abstract][Full Text] [Related]
32. Transmembrane activator and calcium-modulator and cyclophilin ligand interactor mutations in common variable immunodeficiency.
Lee JJ; Ozcan E; Rauter I; Geha RS
Curr Opin Allergy Clin Immunol; 2008 Dec; 8(6):520-6. PubMed ID: 18978466
[TBL] [Abstract][Full Text] [Related]
33. Soluble glucocorticoid-induced tumor necrosis factor receptor (sGITR) stimulates osteoclast differentiation in response to receptor activator of NF-kappaB ligand (RANKL) in osteoclast cells.
Shin HH; Kim SJ; Lee DS; Choi HS
Bone; 2005 May; 36(5):832-9. PubMed ID: 15814301
[TBL] [Abstract][Full Text] [Related]
34. CCR1 acts downstream of NFAT2 in osteoclastogenesis and enhances cell migration.
Ishida N; Hayashi K; Hattori A; Yogo K; Kimura T; Takeya T
J Bone Miner Res; 2006 Jan; 21(1):48-57. PubMed ID: 16355273
[TBL] [Abstract][Full Text] [Related]
35. Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients.
Colucci S; Brunetti G; Mori G; Oranger A; Centonze M; Mori C; Cantatore FP; Tamma R; Rizzi R; Liso V; Zallone A; Grano M
Leukemia; 2009 Nov; 23(11):2139-46. PubMed ID: 19587706
[TBL] [Abstract][Full Text] [Related]
36. Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression.
Liu Z; Xu J; Li H; Zheng Y; He J; Liu H; Zhong Y; Lu Y; Hong B; Zhang M; Lin P; Du J; Hou J; Qian J; Kwak LW; Yi Q; Yang J
PLoS One; 2013; 8(12):e82453. PubMed ID: 24340030
[TBL] [Abstract][Full Text] [Related]
37. Expression and function of chemokine receptors in human multiple myeloma.
Möller C; Strömberg T; Juremalm M; Nilsson K; Nilsson G
Leukemia; 2003 Jan; 17(1):203-10. PubMed ID: 12529679
[TBL] [Abstract][Full Text] [Related]
38. Vγ9Vδ2 T cells inhibit immature dendritic cell transdifferentiation into osteoclasts through downregulation of RANK, c‑Fos and ATP6V0D2.
Zhu X; Zeng Z; Qiu D; Chen J
Int J Mol Med; 2018 Oct; 42(4):2071-2079. PubMed ID: 30066839
[TBL] [Abstract][Full Text] [Related]
39. A proliferation-inducing ligand sustains the proliferation of human naïve (CD27⁻) B cells and mediates their differentiation into long-lived plasma cells in vitro via transmembrane activator and calcium modulator and cyclophilin ligand interactor and B-cell mature antigen.
Matsuda Y; Haneda M; Kadomatsu K; Kobayashi T
Cell Immunol; 2015 Jun; 295(2):127-36. PubMed ID: 25880104
[TBL] [Abstract][Full Text] [Related]
40. APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.
Tai YT; Lin L; Xing L; Cho SF; Yu T; Acharya C; Wen K; Hsieh PA; Dulos J; van Elsas A; Munshi N; Richardson P; Anderson KC
Leukemia; 2019 Feb; 33(2):426-438. PubMed ID: 30135465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
